GI
PLX icon

GAMMA Investing’s Protalix BioTherapeutics PLX Stock Holding History

GAMMA Investing’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$827 Sell
355
-124
-26% -$263 ﹤0.01% 3918
2026
Q1 		$1.04K Buy
479
+124
+35% +$308 ﹤0.01% 3829
2025
Q4 		$639 Buy
+355
New +$726 ﹤0.01% 3882

Other funds holding PLX

SOADOR
State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return
HIM
Harbour Investment Management Edmonds, Washington $194M AUM 15.93% 1-Year Est. Return
OGF
Orin Green Financial San Diego, California $271M AUM 20.78% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
SIC
SJS Investment Consulting Sylvania, Ohio $919M AUM 23.4% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

GAMMA Investing's PLX Position: Q2 2026 in Review

GAMMA Investing reduced its Protalix BioTherapeutics (PLX) stake by 26% in Q2 2026, selling an estimated $263 and leaving 355 shares worth $827. The position accounts for ﹤0.01% of the portfolio, ranked #3918.

GAMMA Investing first reported a position in PLX in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.04K in Q1 2026. 9 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

  • GAMMA Investing held 355 shares of Protalix BioTherapeutics worth $827 as of Q2 2026.
  • GAMMA Investing sold 124 Protalix BioTherapeutics shares in Q2 2026, an estimated $263.
  • Protalix BioTherapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #3918 holding.
  • GAMMA Investing first reported a position in Protalix BioTherapeutics in Q4 2025 and has held it in 3 quarters since.
  • GAMMA Investing's Protalix BioTherapeutics position peaked at $1.04K in Q1 2026.
  • 9 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.